ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,761.00
0.77%
S&P ASX All Technology
3,066.90
-0.26%
Brent Oil
80.915
0.14%
US Dollar vs AUD
1.50529
0.18%
Bitcoin
69,172.00
2.10%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DateTimeSourceHeadlineSymbolCompany
30/05/202406:01GlobeNewswire Inc.Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
24/05/202421:30GlobeNewswire Inc.BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingNASDAQ:BBIOBridgeBio Pharma Inc
18/05/202406:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
15/05/202421:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
14/05/202421:30GlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
13/05/202421:30GlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202421:30GlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202421:00GlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
10/04/202421:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
08/04/202403:15GlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
20/03/202422:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
07/03/202409:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
07/03/202409:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
06/03/202415:53GlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
05/03/202409:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
05/03/202408:17GlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202418:30GlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
23/02/202408:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
22/02/202423:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202423:30GlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202408:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
21/02/202408:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
16/02/202408:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
14/02/202408:05Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
14/02/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
07/02/202423:34GlobeNewswire Inc.BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanNASDAQ:BBIOBridgeBio Pharma Inc
06/02/202423:30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
05/02/202423:30GlobeNewswire Inc.BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
02/02/202423:00GlobeNewswire Inc.BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Your Recent History

ASX
WPL
Woodside Petroleum
NASDAQ
MSFT
Microsoft
FX
AUDCAD
AUD vs CAD
ASX
SUN
Suncorp
CCOM
SILVER
SILVER
ASX
NCM
Newcrest Mining
NYSE
XOM
Exxon Mobil
COIN
BTCUSD
Bitcoin
FX
GBPAUD
Sterling vs AUD
ASX
ANZ
Australia And New Zealan...
ASX
XAO
Australian SE All Ordina...
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
NYSE
JPM
JP Morgan Chase
ASX
WDC
Westfield
ASX
XTO
S&P ASX 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved